Announcement PDF Neuren (NEU) – ASX Announcement 12 December 2024 Priority Review Voucher sale complete Highlights: • Acadia Pharmaceuticals successfully completed the sale of Rare Pediatric Disease Priority Review Voucher (PRV) for US$150m • Neuren to receive one-third of the net proceeds Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) by its partner Acadia Pharmaceuticals (NASDAQ: ACAD) has been successfully completed. The PRV was granted by the U.S. Food and Drug Administration (FDA) following the approval of DAYBUETM (trofinetide) for the treatment of Rett syndrome. On 5 November 2024 ET, Acadia announced the sale of the PRV for US$150m subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Under the license agreement between Acadia and Neuren, Neuren is entitled to receive one-third of the proceeds, net of any applicable costs, which are not expected to be material. About Neuren Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Contact: investorrelations@neurenpharma.com Jon Pilcher, CEO: +61 438 422 271 ASX Listing Rules information This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 1 of 2 Forward-looking Statements This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement. 2 of 2